We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RTX:NYSERTX Corporation Analysis

Data as of 2026-03-09 - not real-time

$209.57

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

RTX is riding a strong bullish technical setup, with the short‑term moving average comfortably above the medium‑term average, an RSI perched in the upper‑mid range and a MACD that has turned bullish, all backed by rising volume. The stock is trading near its 52‑week high, comfortably above the identified support level, and recent geopolitical events have sparked a sector‑wide rally that lifted RTX alongside its peers. Fundamentally, revenue is growing at a healthy pace and cash flow remains robust, supporting a stable dividend payout. However, the price‑earnings multiple sits well above the industry average and a discounted cash‑flow estimate suggests a valuation gap that makes the stock appear overvalued at current levels. Analyst sentiment remains positive, with a consensus buy rating and expectations of modest upside. The company’s recent agreement to expand advanced munitions production adds a concrete growth catalyst tied to heightened defense spending. While debt levels are elevated, the strong operating cash flow and manageable payout ratio indicate that the dividend is likely sustainable for the near term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish technical indicators with price near resistance
  • Sector rally driven by geopolitical tension
  • Overvaluation relative to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained defense spending and order backlog expansion
  • Strong cash flow supporting dividend and debt servicing
  • Positive analyst consensus with modest upside potential

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term demand for aerospace and defense systems
  • Strategic position across multiple defense segments
  • Ability to fund growth and dividends through cash generation

Key Metrics & Analysis

Financial Health

Revenue Growth12.10%
Profit Margin7.60%
P/E Ratio42.3
ROE10.95%
ROA3.88%
Debt/Equity59.51
P/B Ratio4.3
Op. Cash Flow$10.6B
Free Cash Flow$6.5B
Industry P/E29.4

Technical Analysis

TrendBullish
RSI59.3
Support$192.62
Resistance$214.50
MA 20$202.75
MA 50$197.44
MA 200$168.95
MACDBullish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$86.90
Target Price$217.16
Upside/Downside3.62%
GradeOvervalued
TypeGrowth
Dividend Yield1.30%

Risk Assessment

Beta0.56
Volatility29.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.